StockNews.com Downgrades Amicus Therapeutics (NASDAQ:FOLD) to Hold

StockNews.com downgraded shares of Amicus Therapeutics (NASDAQ:FOLD) from a buy rating to a hold rating in a research note released on Friday.

Other analysts also recently issued reports about the company. Morgan Stanley cut their target price on Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Guggenheim boosted their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Bank of America upped their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, October 17th. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, November 7th. Finally, Jefferies Financial Group started coverage on Amicus Therapeutics in a research note on Friday, September 6th. They set a “buy” rating and a $18.00 target price on the stock. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $17.50.

Amicus Therapeutics Trading Down 2.7 %

NASDAQ FOLD opened at $10.69 on Friday. Amicus Therapeutics has a 12 month low of $9.02 and a 12 month high of $14.57. The stock’s fifty day moving average price is $11.11 and its 200-day moving average price is $10.61. The stock has a market cap of $3.19 billion, a P/E ratio of -31.44 and a beta of 0.68. The company has a current ratio of 3.15, a quick ratio of 2.26 and a debt-to-equity ratio of 2.18.

Insider Transactions at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 7,901 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $12.50, for a total transaction of $98,762.50. Following the sale, the chief executive officer now owns 886,654 shares in the company, valued at approximately $11,083,175. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,901 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $12.50, for a total value of $98,762.50. Following the sale, the chief executive officer now owns 886,654 shares in the company, valued at $11,083,175. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $10.60, for a total transaction of $79,500.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $9,398,532.40. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,401 shares of company stock worth $352,038 in the last three months. Insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. OLD Second National Bank of Aurora purchased a new stake in Amicus Therapeutics during the third quarter worth $26,000. Hazlett Burt & Watson Inc. boosted its holdings in Amicus Therapeutics by 156.9% in the third quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 1,569 shares in the last quarter. Blue Trust Inc. grew its position in Amicus Therapeutics by 1,705.4% during the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 2,831 shares during the last quarter. Arcadia Investment Management Corp MI purchased a new stake in shares of Amicus Therapeutics during the third quarter valued at $32,000. Finally, Headlands Technologies LLC purchased a new stake in Amicus Therapeutics during the 2nd quarter valued at about $89,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.